0 5 Oleic oleic JJ 6 10 acid acid NN 11 19 inhibits inhibit VBZ 20 31 endothelial endothelial JJ 32 42 activation activation NN 43 44 : : : 45 46 A a DT 47 53 direct direct JJ 54 62 vascular vascular JJ 63 78 antiatherogenic antiatherogenic JJ 79 88 mechanism mechanism NN 89 91 of of IN 92 93 a a DT 94 105 nutritional nutritional JJ 106 115 component component NN 116 118 in in IN 119 122 the the DT 123 136 mediterranean mediterranean JJ 137 141 diet diet NN 141 142 . . . 144 151 Because because IN 152 157 oleic oleic JJ 158 162 acid acid NN 163 165 is be VBZ 166 176 implicated implicate VBN 177 179 in in IN 180 183 the the DT 184 199 antiatherogenic antiatherogenic JJ 200 207 effects effect NNS 208 218 attributed attribute VBN 219 221 to to TO 222 225 the the DT 226 239 Mediterranean mediterranean JJ 240 244 diet diet NN 244 245 , , , 246 248 we we PRP 249 261 investigated investigate VBD 262 269 whether whether IN 270 274 this this DT 275 280 fatty fatty JJ 281 285 acid acid NN 286 289 can can MD 290 298 modulate modulate VB 299 310 endothelial endothelial JJ 311 321 activation activation NN 321 322 , , , 323 325 ie ie FW 325 326 , , , 327 330 the the DT 331 340 concerted concerted JJ 341 351 expression expression NN 352 354 of of IN 355 359 gene gene NN 360 368 products product NNS 369 377 involved involve VBN 378 380 in in IN 381 390 leukocyte leukocyte NN 391 402 recruitment recruitment NN 403 406 and and CC 407 412 early early JJ 413 426 atherogenesis atherogenesis NN 426 427 . . . 428 430 We we PRP 431 440 incubated incubate VBD 441 447 sodium sodium NN 448 454 oleate oleate NN 455 459 with with IN 460 465 human human JJ 466 475 umbilical umbilical JJ 476 480 vein vein NN 481 492 endothelial endothelial JJ 493 498 cells cell NNS 499 502 for for IN 503 504 0 0 CD 505 507 to to TO 508 510 72 72 CD 511 516 hours hour NNS 516 517 , , , 518 526 followed follow VBN 527 529 by by IN 530 542 coincubation coincubation NN 543 545 of of IN 546 552 oleate oleate NN 553 557 with with IN 558 563 human human JJ 564 575 recombinant recombinant JJ 576 581 tumor tumor NN 582 590 necrosis necrosis NN 591 597 factor factor NN 597 598 , , , 599 610 interleukin interleukin NN 611 612 ( ( ( 612 622 IL)-1alpha IL)-1alpha NNP 622 623 , , , 624 632 IL-1beta IL-1beta NNP 632 633 , , , 634 638 IL-4 il-4 NN 638 639 , , , 640 651 Escherichia escherichia FW 652 656 coli coli FW 657 675 lipopolysaccharide lipopolysaccharide NN 676 677 ( ( ( 677 680 LPS LPS NNP 680 681 ) ) ) 681 682 , , , 683 685 or or CC 686 693 phorbol phorbol NN 694 706 12-myristate 12-myristate NN 707 717 13-acetate 13-acetate NN 718 721 for for IN 722 723 a a DT 724 731 further further JJ 732 733 6 6 CD 734 736 to to TO 737 739 24 24 CD 740 745 hours hour NNS 745 746 . . . 747 750 The the DT 751 762 endothelial endothelial JJ 763 773 expression expression NN 774 776 of of IN 777 785 vascular vascular JJ 786 790 cell cell NN 791 799 adhesion adhesion NN 800 810 molecule-1 molecule-1 NN 811 812 ( ( ( 812 818 VCAM-1 vcam-1 NN 818 819 ) ) ) 819 820 , , , 821 831 E-selectin E-selectin NNP 831 832 , , , 833 836 and and CC 837 850 intercellular intercellular JJ 851 859 adhesion adhesion NN 860 870 molecule-1 molecule-1 NN 871 874 was be VBD 875 884 monitored monitor VBN 885 887 by by IN 888 892 cell cell NN 893 900 surface surface NN 901 907 enzyme enzyme NN 908 920 immunoassays immunoassay NNS 921 923 or or CC 924 928 flow flow NN 929 938 cytometry cytometry NN 938 939 , , , 940 943 and and CC 944 956 steady-state steady-state JJ 957 963 levels level NNS 964 966 of of IN 967 973 VCAM-1 VCAM-1 NNP 974 978 mRNA mRNA NNP 979 983 were be VBD 984 992 assessed assess VBN 993 995 by by IN 996 1004 Northern northern NN 1005 1009 blot blot NN 1010 1018 analysis analysis NN 1018 1019 . . . 1020 1022 At at IN 1023 1025 10 10 CD 1026 1028 to to TO 1029 1032 100 100 CD 1033 1043 micromol/L micromol/l NN 1044 1047 for for IN 1048 1051 >24 >24 CD 1052 1057 hours hour NNS 1057 1058 , , , 1059 1065 oleate oleate NN 1066 1075 inhibited inhibit VBD 1076 1079 the the DT 1080 1090 expression expression NN 1091 1093 of of IN 1094 1097 all all DT 1098 1106 adhesion adhesion NN 1107 1116 molecules molecule NNS 1117 1123 tested test VBN 1123 1124 . . . 1125 1130 After after IN 1131 1132 a a DT 1133 1140 72-hour 72-hour JJ 1141 1151 incubation incubation NN 1152 1156 with with IN 1157 1163 oleate oleate NN 1164 1167 and and CC 1168 1169 a a DT 1170 1177 further further JJ 1178 1185 16-hour 16-hour JJ 1186 1196 incubation incubation NN 1197 1201 with with IN 1202 1208 oleate oleate NN 1209 1213 plus plus CC 1214 1215 1 1 CD 1216 1225 microg/mL microg/ml NN 1226 1229 LPS lps NN 1229 1230 , , , 1231 1237 VCAM-1 vcam-1 NN 1238 1248 expression expression NN 1249 1252 was be VBD 1253 1260 reduced reduce VBN 1261 1263 by by IN 1264 1267 >40 >40 CD 1267 1268 % % NN 1269 1277 compared compare VBN 1278 1282 with with IN 1283 1290 control control NN 1290 1291 . . . 1292 1300 Adhesion Adhesion NNP 1301 1303 of of IN 1304 1314 monocytoid monocytoid JJ 1315 1319 U937 u937 NN 1320 1325 cells cell NNS 1326 1328 to to TO 1329 1340 LPS-treated lps-treated JJ 1341 1352 endothelial endothelial JJ 1353 1358 cells cell NNS 1359 1362 was be VBD 1363 1370 reduced reduce VBN 1371 1384 concomitantly concomitantly RB 1384 1385 . . . 1386 1392 Oleate Oleate NNP 1393 1397 also also RB 1398 1406 produced produce VBD 1407 1408 a a DT 1409 1423 quantitatively quantitatively RB 1424 1431 similar similar JJ 1432 1441 reduction reduction NN 1442 1444 of of IN 1445 1451 VCAM-1 vcam-1 NN 1452 1456 mRNA mrna NN 1457 1463 levels level NNS 1464 1466 on on IN 1467 1475 Northern northern NN 1476 1480 blot blot NN 1481 1489 analysis analysis NN 1490 1493 and and CC 1494 1503 inhibited inhibit VBD 1504 1511 nuclear nuclear JJ 1512 1525 factor-kappaB factor-kappab NN 1526 1536 activation activation NN 1537 1539 on on IN 1540 1555 electrophoretic electrophoretic JJ 1556 1564 mobility mobility NN 1565 1570 shift shift NN 1571 1577 assays assay NNS 1577 1578 . . . 1579 1589 Incubation incubation NN 1590 1592 of of IN 1593 1604 endothelial endothelial JJ 1605 1610 cells cell NNS 1611 1615 with with IN 1616 1622 oleate oleate NN 1623 1626 for for IN 1627 1629 72 72 CD 1630 1635 hours hour NNS 1636 1645 decreased decrease VBD 1646 1649 the the DT 1650 1658 relative relative JJ 1659 1670 proportions proportion NNS 1671 1673 of of IN 1674 1683 saturated saturate VBN 1684 1685 ( ( ( 1685 1693 palmitic palmitic JJ 1694 1697 and and CC 1698 1705 stearic stearic JJ 1705 1706 ) ) ) 1707 1712 acids acid NNS 1713 1715 in in IN 1716 1721 total total JJ 1722 1726 cell cell NN 1727 1733 lipids lipid NNS 1734 1737 and and CC 1738 1747 increased increase VBD 1748 1751 the the DT 1752 1763 proportions proportion NNS 1764 1766 of of IN 1767 1773 oleate oleate NN 1774 1776 in in IN 1777 1782 total total JJ 1783 1787 cell cell NN 1788 1794 lipids lipid NNS 1795 1802 without without IN 1803 1816 significantly significantly RB 1817 1825 changing change VBG 1826 1829 the the DT 1830 1838 relative relative JJ 1839 1850 proportions proportion NNS 1851 1853 of of IN 1854 1869 polyunsaturated polyunsaturated JJ 1870 1875 fatty fatty JJ 1876 1881 acids acid NNS 1881 1882 . . . 1883 1891 Although although IN 1892 1896 less less RBR 1897 1903 potent potent JJ 1904 1908 than than IN 1909 1924 polyunsaturated polyunsaturated JJ 1925 1930 fatty fatty JJ 1931 1936 acids acid NNS 1937 1939 in in IN 1940 1950 inhibiting inhibit VBG 1951 1962 endothelial endothelial JJ 1963 1973 activation activation NN 1973 1974 , , , 1975 1980 oleic oleic JJ 1981 1985 acid acid NN 1986 1989 may may MD 1990 2000 contribute contribute VB 2001 2003 to to TO 2004 2007 the the DT 2008 2018 prevention prevention NN 2019 2021 of of IN 2022 2035 atherogenesis atherogenesis NN 2036 2043 through through IN 2044 2053 selective selective JJ 2054 2066 displacement displacement NN 2067 2069 of of IN 2070 2079 saturated saturated JJ 2080 2085 fatty fatty JJ 2086 2091 acids acid NNS 2092 2094 in in IN 2095 2099 cell cell NN 2100 2108 membrane membrane NN 2109 2122 phospholipids phospholipid NNS 2123 2126 and and CC 2127 2128 a a DT 2129 2139 consequent consequent JJ 2140 2150 modulation modulation NN 2151 2153 of of IN 2154 2158 gene gene NN 2159 2169 expression expression NN 2170 2173 for for IN 2174 2183 molecules molecule NNS 2184 2192 involved involve VBN 2193 2195 in in IN 2196 2204 monocyte monocyte NN 2205 2216 recruitment recruitment NN 2216 2217 . . .